Bioxcel Therapeutics, Inc. (BTAI)

Trade BTAI now with
12/3/2019 7:03:13 AM BioXcel Therapeutics Prepares To Initiate Pivotal Phase 3 Studies With BXCL501
11/14/2019 7:14:26 AM BioXcel Therapeutics Q3 Loss Per Share $0.57 Vs Loss $0.31 Last Year
9/26/2019 9:21:59 AM BioXcel Prices Public Offering Of 2.30 Mln Shares At $8.25 Per Share
9/4/2019 8:13:35 AM BioXcel Receives FDA Orphan Drug Designation For BXCL701 For AML Treatment
7/22/2019 6:02:39 AM BioXcel Therapeutics' BXCL501 Meets Primary Endpoint In Phase 1b Placebo-Controlled Trial
5/7/2019 8:08:42 AM BioXcel Therapeutics Q1 Net Loss $7.2 Mln Vs Loss Of $4.3 Mln Last Year
2/4/2019 8:07:49 AM BioXcel Therapeutics Expands Indication For Lead Neuroscience Asset
1/3/2019 8:25:27 AM BioXcel Therapeutics Reports Positive Human Proof-of-Concept Data For Acute Treatment Of Agitation; Stock Surges
12/27/2018 8:02:04 AM BioXcel Therapeutics Secures FDA Fast Track Designation For BXCL501 For Acute Treatment Of Agitation
12/19/2018 4:15:42 AM BioXcel Doses First Subjects In Pharmacokinetic And Safety Study Of BXCL501 For Acute Treatment Of Agitation
12/12/2018 4:01:00 AM BioXcel Announces FDA Acceptance Of IND For Lead Neuroscience Candidate, BXCL501 For The Acute Treatment Of Agitation
11/14/2018 4:03:21 AM BioXcel Therapeutics Says Positive Results From Phase 1b Study For IV Administered Dexmedetomidine
11/5/2018 4:00:39 AM BioXcel Therapeutics Announces FDA Acceptance Of IND For Lead Immuno-oncology Candidate, BXCL701
10/31/2018 4:05:46 AM BioXcel Therapeutics Says Presentation On Functional Immunological Memory Formation Across Diverse Tumor Types At SITC